Polymorphisms of estrogen-metabolizing genes and breast cancer risk: a multigenic study

被引:0
|
作者
Han, DF
Zhou, X [1 ]
Hu, MB
Xie, W
Mao, ZF
Chen, DE
Liu, F
Zheng, F
机构
[1] Wuhan Univ, Zhongnan Hosp, Clin Lab Ctr, Wuhan 430071, Peoples R China
[2] Wuhan Univ, Zhongnan Hosp, Dept Oncol, Wuhan 430071, Peoples R China
[3] Wuhan Univ, Dept Publ Hlth, Wuhan 430071, Peoples R China
关键词
estrogen; metabolizing genes; polymorphism; breast neoplasms; risk factor;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Endogenous estrogen plays a very important role in the carcinogenesis and progression of breast cancer. The enzymes involved in the biosynthesis and metabolism of estrogen have been proposed to contribute to this effect. To examine this hypothesis, we conducted a case-control study to investigate the relationship between polymorphisms of genes responsible for estrogen biosynthesis (CYP17, cytochrome P450c17a and CYP19, aromatase cytochrome P450) and estrogen sulfation of inactivation (SULT1A1, sulfotransferaselA1) and the risk of breast cancer in Chinese women. Methods This study involved 213 breast cancer patients and 430 matched controls. PCR-based restriction fragment length polymorphism (RFLP) and short tandem repeat polymorphism (STRP) assays were used to detect the mononucleotide transition of CYP17 and SULT1A1 and tandem repeat polymorphism of CYP19. Logistic regression analyses were used to determine OR and 95% Cl of each and all three high-risk genotypes, of all three genotypes combined, and of estrogen exposure factors. The relationship between each high-risk genotype and clinical pathological characteristics were also assessed. Results The frequency of A(2) allele of CYP17 was 49.8% in cases and 49.1% in controls (P = 0.82). The frequency of His allele of SULT1A1 was significantly higher in cases (13.6%) than in controls (9.5%) (P < 0.05). There was also significant difference of the (TTTA)(10) allele of CYP19 which was 12.4% in cases and 8.2% in controls (P < 0.05). When the CYP17 A(2) allele, CYP19 (TTTA)(10) and SULT1A1 His allele were considered as the "putative high-risk" genotype, there was an increased risk of breast cancer with the number of high-risk genotypes in a dose-response effect (trend, P = 0.05). In multivariate analysis, the SULT1A1 genotype remained the most significant determinant for breast cancer, with OR = 2.37 (95% CI 1.23-4.74), followed by CYP19, with OR = 1.75 (95% CI 1.27-3.56). The (TTTA)(10) allele of CYP19 was associated with tumor size, and the His allele of SULT1A1 associated with status of lymph node metastasis. Conclusions This study supports the hypothesis that breast cancer can be initiated by estrogen exposure and that estrogen metabolizing genes are involved in this mechanism. This multigenic model is useful for identifying individuals who are at higher risks of breast cancer.
引用
收藏
页码:1507 / 1516
页数:10
相关论文
共 50 条
  • [31] Investigation of prognostic value of polymorphisms within estrogen metabolizing genes in Lithuanian breast cancer patients
    Savukaityte, Aiste
    Ugenskiene, Rasa
    Jankauskaite, Roberta
    Cereskevicius, Darius
    Sepetauskiene, Egle
    Juozaityte, Elona
    BMC MEDICAL GENETICS, 2015, 16
  • [32] Differential effects of progestogens, by type and regimen, on estrogen-metabolizing enzymes in human breast cancer cells
    Xu, Bing
    Kitawaki, Jo
    Koshiba, Hisato
    Ishihara, Hiroaki
    Kiyomizu, Miyo
    Teramoto, Mariko
    Kitaoka, Yui
    Honjo, Hideo
    MATURITAS, 2007, 56 (02) : 142 - 152
  • [33] Estrogen-metabolizing gene polymorphisms and lipid levels in women with different hormonal status
    Almeida, S
    Zandoná, M
    Franken, N
    Callegari-Jacques, SM
    Osório-Wender, MC
    Hutz, MH
    PHARMACOGENOMICS JOURNAL, 2005, 5 (06): : 346 - 351
  • [34] Polymorphisms of one-carbon-metabolizing genes and risk of breast cancer in a population-based study
    Xu, Xinran
    Gammon, Marilie D.
    Zhang, Heping
    Wetmur, James G.
    Rao, Manlong
    Teitelbaum, Susan L.
    Britton, Julie A.
    Neugut, Alfred I.
    Santella, Regina M.
    Chen, Jia
    CARCINOGENESIS, 2007, 28 (07) : 1504 - 1509
  • [35] Estrogen-metabolizing gene polymorphisms and lipid levels in women with different hormonal status
    S Almeida
    M R Zandoná
    N Franken
    S M Callegari-Jacques
    M C Osório-Wender
    M H Hutz
    The Pharmacogenomics Journal, 2005, 5 : 346 - 351
  • [36] Polymorphisms in the folate-metabolizing genes MTR, MTRR, and CBS and breast cancer risk
    Weiner, Alexandra S.
    Boyarskikh, Uljana A.
    Voronina, Elena N.
    Selezneva, Inna A.
    Sinkina, Tatiana V.
    Lazarev, Alexandr F.
    Petrova, Valentina D.
    Filipenko, Maxim L.
    CANCER EPIDEMIOLOGY, 2012, 36 (02) : E95 - E100
  • [37] Breast cancer risk associated with genotypic polymorphism of the genes involved in the estrogen-receptor-signaling pathway: a multigenic study on cancer susceptibility
    Yu, Jyh-Cherng
    Hsu, Huan-Ming
    Chen, Shou-Tung
    Hsu, Giu-Cheng
    Huang, Chiun-Sheng
    Hou, Ming-Feng
    Fu, Yi-Ping
    Cheng, Ting-Chih
    Wu, Pei-Ei
    Shen, Chen-Yang
    JOURNAL OF BIOMEDICAL SCIENCE, 2006, 13 (03) : 419 - 432
  • [38] Relative imbalances in the expression of estrogen-metabolizing enzymes in the breast tissue of women with breast carcinoma
    Singh, S
    Chakravarti, D
    Edney, JA
    Hollins, RR
    Johnson, PJ
    West, WW
    Higginbotham, SM
    Cavalieri, EL
    Rogan, EG
    ONCOLOGY REPORTS, 2005, 14 (04) : 1091 - 1096
  • [39] Estrogen-metabolizing gene polymorphisms but not estrogen receptor alpha gene polymorphisms are associated with the onset of menarche in healthy postmenopausal Japanese women
    Gorai, I
    Kikuch, R
    Yoshikata, H
    Mochizuki, K
    Chaki, O
    Hirahara, F
    BONE, 2003, 32 (05) : S126 - S127
  • [40] GPER is involved in the regulation of the estrogen-metabolizing CYP1B1 enzyme in breast cancer
    Cirillo, Francesca
    Pellegrino, Michele
    Malivindi, Rocco
    Rago, Vittoria
    Avino, Silvia
    Muto, Luigina
    Dolce, Vincenza
    Vivacqua, Adele
    Rigiracciolo, Damiano Cosimo
    De Marco, Paola
    Sebastiani, Anna
    Abonante, Sergio
    Nakajima, Miki
    Lappano, Rosamaria
    Maggiolini, Marcello
    ONCOTARGET, 2017, 8 (63) : 106608 - 106624